Welcome to our dedicated page for Logicbio Therapeutics news (Ticker: LOGC), a resource for investors and traders seeking the latest updates and insights on Logicbio Therapeutics stock.
ContextLogic Holdings Inc. reports developments as a publicly traded business ownership platform focused on acquiring and building a portfolio of niche, competitively advantaged, long-duration businesses. News about ContextLogic centers on the completed acquisition of US Salt, operating and financial results, acquisition strategy, cash and investment resources, and the company’s evolution into a portfolio ownership model.
Company updates also cover governance and capital-structure matters, including board appointments, audit committee membership, shareholder voting, Delaware reorganization actions, strategic investment arrangements, and securities registration matters. The recurring themes are portfolio ownership, acquisition execution, operating efficiency, and public-company governance.
LogicBio Therapeutics (Nasdaq: LOGC) announced its participation in the Jefferies Virtual Healthcare Conference on June 2, 2020, at 8:00 a.m. ET. The event will feature a live audio webcast available on the company's website, with a replay accessible shortly after the presentation for 30 days.
LogicBio focuses on genome editing to develop medicines for rare pediatric diseases using its GeneRide technology, which enables precise integration of therapeutic transgenes for potentially lifelong expression. More information can be found at www.logicbio.com.
LogicBio Therapeutics (Nasdaq: LOGC) announced its participation in the ASGCT 2020 Annual Meeting, occurring virtually from May 12-15, 2020. The company will present significant data on its GeneRide™ platform, specifically targeting rare diseases in pediatric patients. Highlights include an oral presentation on a methylmalonic acidemia model by Leah Venturoni, alongside multiple poster presentations addressing liver injury, AAV vector development, and gene integration methods. The event reflects LogicBio's commitment to advancing genome editing technologies for effective treatments.
LogicBio Therapeutics (Nasdaq:LOGC) reported its Q1 2020 financial results, highlighting a net loss of $9.5 million, or $0.41 per share, compared to $7.7 million, or $0.34 per share in Q1 2019. R&D expenses rose to $7.2 million, attributed to increased costs for LB-001 and personnel expansion. The firm is advancing LB-001 for methylmalonic acidemia and is in discussions with the FDA for its IND submission. With $43.2 million in cash, LogicBio expects to fund operations through Q2 2021, despite ongoing challenges posed by the COVID-19 pandemic.